Delivery Order SPE2DB20D3303-SPE2DB25FA2DH
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a $12,414.97 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management in patients with obesity or overweight conditions,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors with a ceiling value of $3,812.90. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $81,521.82. This firm fixed-price delivery order represents a non-competitive award under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order is due for completion by August 4, 2025, with performance...
- The Defense Logistics Agency awarded a $3,544.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child contract under...
- The Defense Logistics Agency awarded a $1,525.16 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for supply of Zepbound 10 mg/0.5 mL pen injectors with a completion date of July 30, 2025. This is a firm fixed price delivery order with no set-aside designation, executed under competitive procurement processes. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a tirzepatide-based injectable medication...
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on July 18, 2025, with completion targeted for July 21, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement executed by the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $1,596.72 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pens on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. Zepbound is a tirzepatide injection used for weight management and represents one of numerous pharmaceutical products...
- The Defense Logistics Agency (DLA) awarded a $1,172.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract represents a single delivery order fulfilling federal pharmaceutical procurement needs for military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $2,446.62 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on July 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 31, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a recently approved diabetes and weight management...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2DHDelivery Order
The Defense Logistics Agency awarded a $15,525.98 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, reflecting the federal government's procurement of medications for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates substantial capability in fulfilling diverse pharmaceutical procurement requirements for defense healthcare systems, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.5k | 8/4/25 |